Secnidazole

— Net sales surpassed $20 million mark in FY 2025 — — Income from operations increased to $3.4 million in FY 2025 — SAN DIEGO--(BUSINESS WIRE)-- $EVFM #BV --Women’s health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025. Highlights include: Achieved record net sales of $20.2 million in 2025—Evofem’s fifth consecutive year of net sales growth—mainly driven by sales of PHEXX® (lactic acid, citric acid, and potassium bitartrate) , our hormone-free, on demand contraceptive vaginal gel. Reduced total operating expenses by 38% to $16.8 million in 2025 versus $27.0 million in 2024. The $10.2 million reduction included a $ 5.6 million gain from the settlement of a portion of the Company’s trade payables with vendors, and a $1.9 million non-cash gain on the change in accounting estimates on a contingent royalty liability. Income from operations increased to $3.4 million in 2025, versus a loss from operations of $7.7 million in 2024. Net income attributable to common stockholders increased to $0.3 million, or $0.00 per basic and diluted share, in 2025, versus a net loss of $9.0 million, or ($0.11) per basic and diluted share, in 2024. “In 2025 we delivered our fifth consecutive year of net sales growth, and posted record net sales of more than $20 million, despite ongoing capital constraints. This achievement is a testament to the quality of our products, PHEXX and SOLOSEC, which offer women innovation to address their unmet sexual health needs, and the grit and resilience of our team,” said Saundra Pelletier, CEO of Evofem Biosciences. Additionally, since October 1, 2025: Evofem advanced initiatives to lower manufacturing costs for both products, targeting estimated reductions of 55-60% for PHEXX and SOLOSEC® (secnidazole) 2g oral granules . The Emirates Drug Establishment (EDE) issued favorable pricing certificates for PHEXX, a preliminary administrative step toward anticipated regulatory approval in the United Arab Emirates (UAE). The EDE review of the SOLOSEC application in the UAE is underway. Patient recruitment is ongoing in an investigator-led, NIH-funded Phase 4 clinical trial evaluating the effectiveness and cost-effectiveness of SOLOSEC (single-dose, one time) versus metronidazole (twice daily for seven days) for the treatment of Trichomonas vaginalis in men and women. Study investigators hypothesize that the rate of repeat infections with T. vaginalis will be 1.75 lower in the SOLOSEC group versus the multi-dose oral metronidazole arm and that single-dose SOLOSEC will have higher initial cost but will be more cost effective compared to multi-dose metronidazole, largely due to lower breakthrough rates of infection. 1 Full Year Financial Results For the year ended December 31, 2025, net sales were $20.2 million compared to $19.4 million in the prior year. The 4% increase reflects the higher PHEXX wholesale average cost (WAC) and slight improvement in gross-to-net ratio. SOLOSEC net sales also contributed to the increase, with a full year of sales in 2025 vs. 5.5 months in the prior year; Evofem acquired the single-dose oral STI treatment in July 2024 and relaunched it in the U.S. in late 2024. Total operating expenses were $16.8 million, a $10.2 million reduction compared to the prior year which was driven by: A $5.3 million reduction in research and development expenses in 2025 due to the settlement of a portion of our trade payables and accrued liabilities, partially offset by an uptick in outside services costs; A $4.2 million reduction in general and administrative expenses in 2025 vs. 2024; and A one-time gain of $1.9 million in 2025 due to the expiration of the Rush patent and related royalty, which triggered a change in the accounting estimate for the contingent royalty liability. These aggregate savings were partially offset by a $0.5 million uptick in selling and marketing expenses in 2025 versus 2024. The increase reflects a full year of PDUFA fees, 3PL fees, and other commercial costs for SOLOSEC in 2025 vs. 5.5 months in 2024. As a result, Evofem reported $3.4 million of operating income in 2025, compared to a loss from operations of $7.7 million in the prior year. Net income attributable to common stockholders increased to $0.3 million, or $0.00 per basic and diluted share, in 2025, versus a net loss of $9.0 million, or ($0.11) per basic and diluted share, in 2024. Fourth Quarter Financial Results For the three months ended December 31, 2025, net sales were $9.6 million, versus $7.1 million in the prior year period. The 35% increase predominantly reflects the higher PHEXX WAC, more favorable gross-to-net ratio, and higher PHEXX ex-factory unit sales in the 2025 period. Total operating expenses decreased to $6.2 million in the fourth quarter of 2025 as compared to $8.1 million in the prior year period. Lower general and administrative and research and development expenses were offset in part by a $1.1 million increase in cost of goods sold (COGS), to a lesser extent, higher PHEXX sales in the 2025 period. As a result, Evofem reported $3.3 million of operating income for the fourth quarter of 2025, versus a loss from operations of $1.0 million in the prior year period. Net income was $2.8 million, or $0.02 per basic and $0.00 per diluted share, in the fourth quarter of 2025, versus a net loss of $3.0 million, or ($0.03) per basic and diluted share, for the fourth quarter of 2024. About Evofem Evofem Biosciences is a San Diego-based pharmaceutical company commercializing two FDA-approved sexual and reproductive health products: PHEXX ® (lactic acid, citric acid, and potassium bitartrate) - the first and only hormone-free, on-demand prescription contraceptive vaginal gel. Visit phexx.com to learn more and for important safety information. SOLOSEC® (secnidazole) 2 g oral granules - an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information. PHEXX® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, “anticipate,” “could,” “estimate,” “expect,” “target,” “hypothesize,” “intend,” “potential,” “strategy,” “will,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to, Evofem’s expectations regarding the anticipated impact of COGS reduction initiatives, the timing and outcome of the EDE review of the submissions for PHEXX and SOLOSEC in the UAE, and the commercialization of PHEXX and SOLOSEC. Forward-looking statements are based on current assumptions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements include, but are not limited to, limited cash resources, the Company’s ability to continue as a going concern, dependence on new capital or business development transactions to fund operations, potential delays in regulatory approvals, changes in market demand, manufacturing and supply chain risks, and the nonrecurring nature of certain recent gains, together with those that are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 11, 2026 and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. Evofem undertakes no obligation to update or revise any forward-looking statement except as required by law, and investors are cautioned not to place undue reliance on such statements given the Company’s current liquidity position and evolving business conditions. Sources National Institute of Allergy & Infectious Diseases (NIAID) of the National Institutes of Health. Award number R01AI183266 : Refining Trichomonas vaginalis treatment in women and men. Click here for financial tables Contacts Connect with Us ir@evofem.com media@evofem.com

-- Evofem Shareholders Did Not Approve the Merger with Aditxt -- -- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales -- SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) ("Evofem" or the "Company"), today announced that at a Special Meeting of Stockholders held this morning, its stockholders did not approve the proposal to adopt the Amended and Restated Merger Agreement dated July 12, 2024, as subsequently amended (the "Merger Agreement"), between the Company, Aditxt, Inc. (NASDAQ: ADTX), and Adifem, Inc., a wholly owned subsidiary of Aditxt, under which Aditxt intended to acquire Evofem. As a result, Evofem has exercised its rights to terminate the Merger Agreement. "With the outcome of this meeting, we are pivoting to focus our efforts on regaining a national listing for Evofem's stock and securing capital to catalyze our growth trajectory and better position us to deliver sustainable positive EBITDA in 2027," said Saundra Pelletier, CEO of Evofem Biosciences. "We are grateful to Aditxt for its support of Evofem and our mission through its meaningful investments, and we look forward to a fruitful collaboration to commercialize the Mitomic™ diagnostic tests for women's health conditions , including endometriosis and ovarian cancer, under our September 2024 agreement." Evofem is taking steps to execute its long-term growth strategy with emphasis on delivering value for investors and the women and healthcare providers who rely on its products for their sexual health needs. The Company commercializes two FDA-approved sexual health products: PHEXXI® (lactic acid, citric acid, and potassium bitartrate) vaginal gel for hormone-free, on-demand contraception, and SOLOSEC® (secnidazole) 2 g oral granules, a single dose oral 5-nitroimidazole drug indicated for the treatment of bacterial vaginosis (BV) in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. 2024 was its fourth consecutive year of net sales growth. About Evofem Biosciences Evofem Biosciences, Inc. is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products: PHEXXI® (lactic acid, citric acid, and potassium bitartrate) is the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Visit phexxi.com to learn more and for important safety information. SOLOSEC® (secnidazole) 2 g oral granules is an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information. PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "anticipate," "aim," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include those related to Evofem's strategic plans, including regaining a national listing for its stock, securing capital to catalyze its growth trajectory, and the anticipated achievement of sustainable positive EBITDA and timing thereof as well as the anticipated regulatory clearance of the Mitomic diagnostic tests and expected collaboration with Aditxt to commercialize them. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements include, without limitation: the potential impacts on the Company's business, results of operations, and financial condition as a result of the termination of the Merger Agreement and Merger or any challenges to such termination; litigation that may arise from or in connection with the now-terminated Merger Agreement, if any; the risk that any announcements relating to the terminated Merger could have adverse effects on the market price of the Company's common shares; the Company's ability to repay its senior debt holders; the Company's ability to pay the significant costs, expenses, and fees for professional services and other costs in connection with the terminated Merger; the risk that the terminated Merger could have an adverse effect on the ability of the Company to retain and maintain relationships with customers, suppliers, and other business partners; the Company's success in regaining a national listing for its stock; its success in securing sufficient capital to catalyze its growth trajectory; the Company's anticipated sales growth; its ability to attract and retain sales representatives and other personnel; the ability of the commercial organization to deliver the anticipated results; and other factors that are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 24, 2025, amended on March 28, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law. Contact Amy Raskopf Chief Business Development Officer Evofem Biosciences, Inc. [email protected] (917) 673-5775 SOURCE Evofem Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED